PKO Investment Management Joint Stock Co decreased its position in Humana Inc. (NYSE:HUM - Free Report) by 42.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,000 shares of the insurance provider's stock after selling 1,500 shares during the quarter. PKO Investment Management Joint Stock Co's holdings in Humana were worth $529,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also bought and sold shares of the company. Rakuten Securities Inc. lifted its holdings in shares of Humana by 50.0% in the 1st quarter. Rakuten Securities Inc. now owns 300 shares of the insurance provider's stock worth $79,000 after acquiring an additional 100 shares during the last quarter. QRG Capital Management Inc. lifted its stake in Humana by 29.0% in the first quarter. QRG Capital Management Inc. now owns 2,765 shares of the insurance provider's stock worth $732,000 after purchasing an additional 621 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Humana in the first quarter worth $1,309,000. Bank Pictet & Cie Europe AG purchased a new stake in Humana during the first quarter valued at about $214,000. Finally, Exchange Traded Concepts LLC grew its stake in shares of Humana by 8.0% during the first quarter. Exchange Traded Concepts LLC now owns 1,286 shares of the insurance provider's stock valued at $340,000 after buying an additional 95 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.
Humana Price Performance
Shares of NYSE HUM opened at $241.38 on Wednesday. Humana Inc. has a 1 year low of $212.45 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. The company's 50-day moving average is $248.65 and its 200 day moving average is $261.84. The stock has a market capitalization of $29.13 billion, a P/E ratio of 17.07, a P/E/G ratio of 1.78 and a beta of 0.43.
Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The business had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. During the same period in the previous year, the firm posted $7.23 EPS. The business's revenue was up 8.4% on a year-over-year basis. On average, sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.
Humana Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.47%. Humana's payout ratio is 25.04%.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on HUM. Wall Street Zen lowered Humana from a "buy" rating to a "hold" rating in a research note on Saturday. Mizuho boosted their price objective on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Robert W. Baird increased their price objective on Humana from $270.00 to $300.00 and gave the company a "neutral" rating in a research note on Tuesday, April 15th. Barclays set a $268.00 target price on shares of Humana and gave the stock an "equal weight" rating in a research note on Thursday, June 12th. Finally, Truist Financial dropped their price target on shares of Humana from $305.00 to $280.00 and set a "hold" rating for the company in a research report on Tuesday. Seventeen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Humana presently has an average rating of "Hold" and an average target price of $280.76.
View Our Latest Analysis on HUM
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
